Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Harari

Showing results (241-250 of 305) with videos related to

Pageof 31
Sort By:
Head and Neck Pathology|October 22, 2024
Uncommon and Challenging Phenotypes of High-Risk Human Papillomavirus-Associated Head and Neck Carcinomas Revealed by High-Throughput StudiesAlex P Tannenbaum, Taja Lozar, Changxue Lu, et al.
Plos One|August 13, 2013
The relative expression of Mig6 and EGFR is associated with resistance to EGFR kinase inhibitorsXiaofei Chang, Eugene Izumchenko, Luisa M Solis, et al.
NPJ Genomic Medicine|October 17, 2022
Identification of phenocopies improves prediction of targeted therapy response over DNA mutations aloneHamza Bakhtiar, Kyle T Helzer, Yeonhee Park, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 9, 2014
Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234Paul M Harari, Jonathan Harris, Merrill S Kies, et al.
Cancers|October 2, 2020
Blocking Y-Box Binding Protein-1 through Simultaneous Targeting of PI3K and MAPK in Triple Negative Breast CancersAadhya Tiwari, Mari Iida, Corinna Kosnopfel, et al.
JNCI Cancer Spectrum|January 22, 2026
STING predicts patterns of failure in locally advanced head and neck squamous cell carcinomaTyler MacNeil, Thomas J Hayman, Shengguo Li, et al.
International Journal of Radiation Oncology, Biology, Physics|February 10, 2015
Phase 1 trial of bevacizumab with concurrent chemoradiation therapy for squamous cell carcinoma of the head and neck with exploratory functional imaging of tumor hypoxia, proliferation, and perfusionMatthew J Nyflot, Tim J Kruser, Anne M Traynor, et al.
Cancer|May 21, 2016
Increased tumor response to neoadjuvant therapy among rectal cancer patients taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockersZachary S Morris, Sandeep Saha, William J Magnuson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 18, 2012
Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neckA Argiris, A P Kotsakis, T Hoang, et al.
The Lancet. Oncology|November 10, 2009
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survivalJames A Bonner, Paul M Harari, Jordi Giralt, et al.
Pageof 31

Showing results (241-250 of 305) with videos related to

Sort By:
Pageof 31
Head and Neck Pathology|October 22, 2024
Uncommon and Challenging Phenotypes of High-Risk Human Papillomavirus-Associated Head and Neck Carcinomas Revealed by High-Throughput StudiesAlex P Tannenbaum, Taja Lozar, Changxue Lu, et al.
Plos One|August 13, 2013
The relative expression of Mig6 and EGFR is associated with resistance to EGFR kinase inhibitorsXiaofei Chang, Eugene Izumchenko, Luisa M Solis, et al.
NPJ Genomic Medicine|October 17, 2022
Identification of phenocopies improves prediction of targeted therapy response over DNA mutations aloneHamza Bakhtiar, Kyle T Helzer, Yeonhee Park, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 9, 2014
Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234Paul M Harari, Jonathan Harris, Merrill S Kies, et al.
Cancers|October 2, 2020
Blocking Y-Box Binding Protein-1 through Simultaneous Targeting of PI3K and MAPK in Triple Negative Breast CancersAadhya Tiwari, Mari Iida, Corinna Kosnopfel, et al.
JNCI Cancer Spectrum|January 22, 2026
STING predicts patterns of failure in locally advanced head and neck squamous cell carcinomaTyler MacNeil, Thomas J Hayman, Shengguo Li, et al.
International Journal of Radiation Oncology, Biology, Physics|February 10, 2015
Phase 1 trial of bevacizumab with concurrent chemoradiation therapy for squamous cell carcinoma of the head and neck with exploratory functional imaging of tumor hypoxia, proliferation, and perfusionMatthew J Nyflot, Tim J Kruser, Anne M Traynor, et al.
Cancer|May 21, 2016
Increased tumor response to neoadjuvant therapy among rectal cancer patients taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockersZachary S Morris, Sandeep Saha, William J Magnuson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 18, 2012
Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neckA Argiris, A P Kotsakis, T Hoang, et al.
The Lancet. Oncology|November 10, 2009
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survivalJames A Bonner, Paul M Harari, Jordi Giralt, et al.
Pageof 31